|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ding B, Wahid MA, Wang Z, Xie C, Thakkar
A, Prabhu S and Wang J: Triptolide and celastrol loaded silk
fibroin nanoparticles show synergistic effect against human
pancreatic cancer cells. Nanoscale. 9:11739–11753. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soranna D, Scotti L, Zambon A, Bosetti C,
Grassi G, Catapano A, La Vecchia C, Mancia G and Corrao G: Cancer
risk associated with use of metformin and sulfonylurea in type 2
diabetes: A meta-analysis. Oncologist. 17:813–822. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan
M and Li D: Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clin Cancer Res.
18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bodmer M, Becker C, Meier C, Jick SS and
Meier CR: Use of antidiabetic agents and the risk of pancreatic
cancer: A case-control analysis. Am J Gastroenterol. 107:620–626.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohammed A, Janakiram NB, Brewer M,
Ritchie RL, Marya A, Lightfoot S, Steele VE and Rao CV:
Antidiabetic drug metformin prevents progression of pancreatic
cancer by targeting in part cancer stem cells and mTOR signaling.
Transl Oncol. 6:649–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karnevi E, Said K, Andersso R and
Rosendahl AH: Metformin-mediated growth inhibition involves
suppression of the IGF-I receptor signalling pathway in human
pancreatic cancer cells. BMC Cancer. 13:2352013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith
J and Rozengurt E: Different patterns of Akt and ERK feedback
activation in response to rapamycin, active-site mTOR inhibitors
and metformin in pancreatic cancer cells. PLoS One. 8:e572892013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vallianou NG, Evangelopoulos A and Kazazis
C3: Metformin and cancer. Rev Diabet Stud. 10:228–235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cifarelli V, Lashinger LM, Devlin KL,
Dunlap SM, Huang J, Kaaks R, Pollak MN and Hursting SD: Metformin
and rapamycin reduce pancreatic cancer growth in obese prediabetic
mice by distinct microRNA-regulated mechanisms. Diabetes.
64:1632–1642. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
National Research Council, . Guide for the
Care and Use of Laboratory Animals. 8th. National Acadamies Press;
Washington, DC: 2011, PubMed/NCBI
|
|
14
|
Simon R, Mirlacher M and Sauter G:
Immunohistochemical analysis of tissue microarrays. Methods Mol
Biol. 664:113–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou TC and Martin N: CompuSyn for drug
combinations and for general dose-effect analysis. Combosyn, Inc.;
Paramus, NJ: 2005
|
|
17
|
Guertin DA and Sabatini DM: An expanding
role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rice S, Pellat L, Ahmetaga A, Bano G,
Mason HD and Whitehead SA: Dual effect of metformin on growth
inhibition and oestradiol productionin breast cancer cells. Int J
Mol Med. 35:1088–1094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zakikhani M, Blouin MJ, Piura E and Pollak
MN: Metformin and rapamycin have distinct effects on the AKT
pathway and proliferation in breast cancer cells. Breast Cancer Res
Treat. 123:271–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saha A, Blando J, Tremmel L and DiGiovanni
J: Effect of metformin, rapamycin, and their combination on growth
and progression of prostate tumors in HiMyc mice. Cancer Prev Res
(Phila). 8:597–606. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Wei J, Li L, Fan C and Sun Y:
Combined use of metformin and everolimus is synergistic in the
treatment of breast cancer cells. Oncol Res. 22:193–201. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y,
Wang LJ, He DH, Zhao Y, Wu WJ, et al: Metformin displays
anti-myeloma activity and synergistic effect with dexamethasone in
in vitro and in vivo xenograft models. Cancer Lett. 356:443–453.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanly EK, Bednarczyk RB, Tuli NY,
Moscatello AL, Halicka HD, Li J, Geliebter J, Darzynkiewicz Z and
Tiwari RK: mTOR inhibitors sensitize thyroid cancer cells to
cytotoxic effect of vemurafenib. Oncotarget. 6:39702–39713. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Brien AJ, Villani LA, Broadfield LA,
Houde VP, Galic S, Blandino G, Kemp BE, Tsakiridis T, Muti P and
Steinberg GR: Salicylate activates AMPK and synergizes with
metformin to reduce the survival of prostate and lung cancer cells
ex vivo through inhibition of de novo lipogenesis. Biochem J.
469:177–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue W, Zheng X, Lin Y, Yang CS, Xu Q,
Carpizo D, Huang H, DiPaola RS and Tan XL: Metformin combined with
aspirin significantly inhibit pancreatic cancer cell growth in
vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and
Bcl-2. Oncotarget. 6:21208–21224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ling S, Feng T, Ke Q, Fan N, Li L, Li Z,
Dong C, Wang C, Xu F, Li Y and Wang L: Metformin inhibits
proliferation and enhances chemosensitivity of intrahepatic
cholangiocarcinoma cell lines. Oncol Rep. 31:2611–2618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ling S, Tian Y, Zhang H, Jia K, Feng T,
Sun D, Gao Z, Xu F, Hou Z, Li Y and Wang L: Metformin reverses
multidrug resistance in human hepatocellular carcinoma
Bel-7402/5-fluorouracil cells. Mol Med Rep. 10:2891–2897. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu M, Zhang Q, Wang X, Kang L, Yang Y,
Liu Y, Yang L, Li J, Yang L, Liu J, et al: Metformin potentiates
anti-tumor effect of resveratrol on pancreatic cancer by
down-regulation of VEGF-B signaling pathway. Oncotarget.
7:84190–84200. 2016.PubMed/NCBI
|
|
30
|
Driscoll DR, Karim SA, Sano M, Gay DM,
Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, et
al: mTORC2 Signaling drives the development and progression of
pancreatic cancer. Cancer Res. 76:6911–6923. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lipner MB, Marayati R, Deng Y, Wang X,
Raftery L, O'Neil BH and Yeh JJ: Metformin treatment does not
inhibit growth of pancreatic cancer patient-derived Xenografts.
PLoS One. 11:e01471132016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei F, Zhang Y, Geng L, Zhang P, Wang G
and Liu Y: mTOR inhibition induces EGFR feedback activation in
association with its resistance to human pancreatic cancer. Int J
Mol Sci. 16:3267–3282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zagouri F, Sergentanis TN, Chrysikos D,
Zografos CG, Papadimitriou CA, Dimopoulos MA, Filipits M and
Bartsch R: Molecularly targeted therapies in metastatic pancreatic
cancer: A systematic review. Pancreas. 42:760–773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garrido-Laguna I, Tan AC, Uson M,
Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A,
Donehower R, et al: Integrated preclinical and clinical development
of mTOR inhibitors in pancreatic cancer. Br J Cancer. 103:649–655.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Javle MM, Shroff RT, Xiong H, Varadhachary
GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA and Abbruzzese
JL: Inhibition of the mammalian target of rapamycin (mTOR) in
advanced pancreatic cancer: Results of two phase II studies. BMC
Cancer. 10:3682010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wolpin BM, Hezel AF, Abrams T, Blaszkowsky
LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP
and Fuchs CS: Oral mTOR inhibitor everolimus in patients with
gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol.
27:193–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
